Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Odyssey Therapeutics, Inc.ODTX · Entity 4850 | Director | May 07, 2026 | May 12, 2026 |
| QUEST DIAGNOSTICS INCDGX · Entity 2118 | Director | May 29, 2018 | May 30, 2018 |
| Revolution Healthcare Acquisition Corp.REVH · Entity 135631 | Director | March 17, 2021 | March 17, 2021 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director · Executive Chairman | February 24, 2026 | February 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Odyssey Therapeutics, Inc.
Report date May 07, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 270,198 |
Reported balance
After 2026-05-08 transaction · row 1
1 source rowRow 1 · 2026-05-08 · Purchase · Acquired 5,000 · Balance 270,198 |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 31,644 |
Last balance in matching sequence
After 2026-05-11 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 2 · 2026-05-11 · Conversion · Acquired 28,698 · Balance 28,698 F1: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration. F2: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F3: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. Row 3 · 2026-05-11 · Exercise / conversion · Acquired 2,963 · Balance 31,661 F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. Row 4 · 2026-05-11 · Tax withholding · Disposed 17 · Balance 31,644 F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. F6: Pursuant to the terms of the warrants, the Issuer withheld 17 warrant shares to pay the exercise price in connection with the net exercise. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-05-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-11 · Conversion · Disposed 79,166 · Balance 0 F1: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration. F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-05-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-11 · Conversion · Disposed 100,000 · Balance 0 F2: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
| Series D Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-05-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-05-11 · Conversion · Disposed 96,002 · Balance 0 F3: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-05-06 | Direct | 626,220 |
Reported balance
After 2026-05-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-05-07 · Grant · Acquired 626,220 · Balance 626,220 F8: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date. |
| Series D Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.10 | IndirectSee footnote | 0 |
Reported balance
After 2026-05-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-05-11 · Exercise / conversion · Disposed 28,800 · Balance 0 F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration.
F2: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
F3: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities.
F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis.
F6: Pursuant to the terms of the warrants, the Issuer withheld 17 warrant shares to pay the exercise price in connection with the net exercise.
F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering.
F8: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.
QUEST DIAGNOSTICS INC
Report date May 29, 2018 · Filed May 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,000 |
Reported balance
After 2018-05-29 transaction · row 1
1 source rowRow 1 · 2018-05-29 · Sale · Disposed 1,644 · Balance 6,000 |
Revolution Healthcare Acquisition Corp.
Report date March 17, 2021 · Filed March 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B common stockSEC Table I · non-derivative | IndirectBy Racing Beach Ventures LLC | 7,500 |
Reported balance
Holding disclosure · report date 2021-03-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 7,500 F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-253729), as amended, under the heading "Description of Securities - Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the Issuer after the consummation of the Issuer's initial business combination. F2: Shares held directly by Racing Beach Ventures LLC. The Reporting Person is a managing member of Racing Beach Ventures LLC and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-253729), as amended, under the heading "Description of Securities - Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the Issuer after the consummation of the Issuer's initial business combination.
F2: Shares held directly by Racing Beach Ventures LLC. The Reporting Person is a managing member of Racing Beach Ventures LLC and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
VERTEX PHARMACEUTICALS INC / MA
Report date February 24, 2026 · Filed February 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,797 |
Reported balance
After 2026-02-24 transaction · row 1
1 source rowRow 1 · 2026-02-24 · Tax withholding · Disposed 3,547 · Balance 34,797 |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 440 |
Reported balance
Holding disclosure · report date 2026-02-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 440 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABBOTT LABORATORIES
Report date March 24, 2006 · Filed March 28, 2006
Section 16 reporting ended · disclosed 2006-03-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 209,401 |
Ending reported balance
After 2006-03-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2006-03-24 · Tax withholding · Disposed 91,846 · Balance 309,401 Row 2 · 2006-03-24 · Disposition to issuer · Disposed 100,000 · Balance 209,401 |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 635 |
Reported balance
Holding disclosure · report date 2006-03-24 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 635 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of March 24, 2006. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of March 24, 2006.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2017 Filed Jun 5, 2017 22:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 22,500 | $53.85 | $1,211,625.00 |
DisclosureSEC source: 0001209191-17-037920 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2017 Filed May 18, 2017 20:43 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 1,573 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-17-000135 · wf-form4_149514017523365.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,600 Read SEC document |
| April 28, 2017 Filed Apr 28, 2017 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $34.05 | $0.00 |
DisclosureSEC source: 0001209191-17-028749 · doc4.xml · derivative · entry 10 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2019-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| April 28, 2017 Filed Apr 28, 2017 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $34.24 | $0.00 |
DisclosureSEC source: 0001209191-17-028749 · doc4.xml · derivative · entry 9 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2020-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| April 28, 2017 Filed Apr 28, 2017 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,527 | $0.00 Strike: $34.39 | $0.00 |
DisclosureSEC source: 0001209191-17-028749 · doc4.xml · derivative · entry 8 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,527 shares Expires 2020-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| April 28, 2017 Filed Apr 28, 2017 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 88,507 | $0.00 Strike: $29.98 | $0.00 |
DisclosureSEC source: 0001209191-17-028749 · doc4.xml · derivative · entry 7 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,601 Underlying: Common Stock · 88,507 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| April 28, 2017 Filed Apr 28, 2017 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 157,200 | $119.50 | $18,785,400.00 |
DisclosureSEC source: 0001209191-17-028749 · doc4.xml · nonDerivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,479 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $119.50 (range $119.50 to $119.60). Read SEC document |
| April 28, 2017 Filed Apr 28, 2017 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 30,000 | $34.05 | $1,021,500.00 |
DisclosureSEC source: 0001209191-17-028749 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2017 Filed Apr 28, 2017 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 20,000 | $34.24 | $684,800.00 |
DisclosureSEC source: 0001209191-17-028749 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2017 Filed Apr 28, 2017 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,527 | $34.39 | $52,513.53 |
DisclosureSEC source: 0001209191-17-028749 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2017 Filed Apr 28, 2017 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 88,507 | $29.98 | $2,653,439.86 |
DisclosureSEC source: 0001209191-17-028749 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $88.39 | $8,839.00 |
DisclosureSEC source: 0001209191-17-011115 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,645 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 23,804 | $87.68 | $2,087,134.72 |
DisclosureSEC source: 0001209191-17-011115 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,745 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $87.68 (range $87.29 to $88.23). Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 103,550 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-17-008377 · doc4.xml · derivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,550 Underlying: Common Stock · 103,550 shares Expires 2027-02-02 F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 50,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008377 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,549 F2 · shares: Restricted stock unit award that vests in three equal installments on 2/10/2018, 2/10/2019 and 2/10/2020. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 17,895 | $0.01 | $178.95 |
DisclosureSEC source: 0001209191-17-008377 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,982 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/02/2016 that contained both performance-vesting and service-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2017. The earned performance shares remain subject to the service-vesting requirements and will vest in three equal installments on 2/10/2017, 2/10/2018 and 2/10/2019. Read SEC document |
| February 03, 2016 Filed Feb 4, 2016 23:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,034 | $92.87 | $96,027.58 |
DisclosureSEC source: 0001209191-16-095842 · doc4.xml · nonDerivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,885 F2 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F4 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $92.87 (range $92.50 to $93.11). Read SEC document |
| February 03, 2016 Filed Feb 4, 2016 23:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 900 | $91.96 | $82,764.00 |
DisclosureSEC source: 0001209191-16-095842 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,919 F2 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F4 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $91.96 (range $91.40 to $92.37). Read SEC document |
| February 03, 2016 Filed Feb 4, 2016 23:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,700 | $91.01 | $336,737.00 |
DisclosureSEC source: 0001209191-16-095842 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,819 F2 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F4 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $91.01 (range $90.37 to $91.33). Read SEC document |
| February 03, 2016 Filed Feb 4, 2016 23:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,200 | $89.91 | $377,622.00 |
DisclosureSEC source: 0001209191-16-095842 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,519 F2 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Open market sales reported on this line occurred at a weighted average price of $89.91 (range $89.31 to $90.27). F4 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 02, 2016 Filed Feb 4, 2016 23:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 107,276 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-16-095842 · doc4.xml · derivative · entry 7 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,276 Underlying: Common Stock · 107,276 shares Expires 2026-02-01 F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2016. Read SEC document |
| February 02, 2016 Filed Feb 4, 2016 23:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 53,817 | $0.01 | $538.17 |
DisclosureSEC source: 0001209191-16-095842 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,719 F1 · shares: Restricted stock unit award that vests in three equal installments on 2/10/2017, 2/10/2018 and 2/10/2019. Read SEC document |
| January 11, 2016 Filed Jan 15, 2016 02:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GiftStock Option (right to buy) · Derivative | 110,625 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-16-091547 · doc4.xml · derivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · Common Stock held in trust Disclosed balance after: 110,625 Underlying: Common Stock · 110,625 shares Expires 2023-02-04 F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/5/2013. F2 · balance_after: Gift of options held by Dr. Leiden to a grantor retained annuity trust for the benefit of his immediate family members. Dr. Leiden maintains beneficial ownership over the shares subject to the options. Read SEC document |
| January 11, 2016 Filed Jan 15, 2016 02:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GiftStock Option (right to buy) · Derivative | 110,625 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-16-091547 · doc4.xml · derivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,375 Underlying: Common Stock · 110,625 shares Expires 2023-02-04 F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/5/2013. F2 · balance_after: Gift of options held by Dr. Leiden to a grantor retained annuity trust for the benefit of his immediate family members. Dr. Leiden maintains beneficial ownership over the shares subject to the options. Read SEC document |
| January 11, 2016 Filed Jan 15, 2016 02:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GiftStock Option (right to buy) · Derivative | 88,500 | $0.00 Strike: $48.74 | $0.00 |
DisclosureSEC source: 0001209191-16-091547 · doc4.xml · derivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · Common Stock held in trust Disclosed balance after: 88,500 Underlying: Common Stock · 88,500 shares Expires 2022-07-24 F1 · derivative.exercise_date: The option vests in 16 quarterly installments from 7/25/2012. F2 · balance_after: Gift of options held by Dr. Leiden to a grantor retained annuity trust for the benefit of his immediate family members. Dr. Leiden maintains beneficial ownership over the shares subject to the options. Read SEC document |
| January 11, 2016 Filed Jan 15, 2016 02:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GiftStock Option (right to buy) · Derivative | 88,500 | $0.00 Strike: $48.74 | $0.00 |
DisclosureSEC source: 0001209191-16-091547 · doc4.xml · derivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,500 Underlying: Common Stock · 88,500 shares Expires 2022-07-24 F1 · derivative.exercise_date: The option vests in 16 quarterly installments from 7/25/2012. F2 · balance_after: Gift of options held by Dr. Leiden to a grantor retained annuity trust for the benefit of his immediate family members. Dr. Leiden maintains beneficial ownership over the shares subject to the options. Read SEC document |
| November 18, 2015 Filed Nov 20, 2015 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 16,125 | $130.00 | $2,096,250.00 |
DisclosureSEC source: 0001209191-15-081535 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,902 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| October 30, 2015 Filed Nov 3, 2015 23:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $126.86 | $25,372.00 |
DisclosureSEC source: 0001209191-15-078176 · doc4.xml · nonDerivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,923 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $126.86 (range $126.85 to $126.87). Read SEC document |
| October 30, 2015 Filed Nov 3, 2015 23:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 8,125 | $126.31 | $1,026,268.75 |
DisclosureSEC source: 0001209191-15-078176 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,123 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $126.31 (range $125.85 to $126.81). Read SEC document |
| October 30, 2015 Filed Nov 3, 2015 23:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,800 | $125.35 | $601,680.00 |
DisclosureSEC source: 0001209191-15-078176 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,248 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $125.35 (range $124.85 to $125.84). Read SEC document |
| October 30, 2015 Filed Nov 3, 2015 23:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,400 | $124.33 | $174,062.00 |
DisclosureSEC source: 0001209191-15-078176 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,048 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $124.33 (range $123.83 to $124.74). Read SEC document |
| October 30, 2015 Filed Nov 3, 2015 23:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,600 | $123.34 | $197,344.00 |
DisclosureSEC source: 0001209191-15-078176 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,448 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $123.34 (range $122.82 to $123.79). Read SEC document |
| July 21, 2015 Filed Jul 23, 2015 20:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 106,500 | $0.00 Strike: $131.89 | $0.00 |
DisclosureSEC source: 0001209191-15-062183 · doc4.xml · derivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,500 Underlying: Common Stock · 106,500 shares Expires 2025-07-20 F1 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/21/2015. Read SEC document |
| February 18, 2015 Filed Feb 20, 2015 21:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 15,250 | $113.14 | $1,725,385.00 |
DisclosureSEC source: 0001209191-15-016642 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,927 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $113.14 (range $112.99 to $113.57). Read SEC document |
| February 18, 2015 Filed Feb 20, 2015 21:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 17,000 | $112.67 | $1,915,390.00 |
DisclosureSEC source: 0001209191-15-016642 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,177 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $112.67 (range $111.99 to $112.98). F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 03, 2015 Filed Feb 5, 2015 22:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (right to buy) · Derivative | 213,000 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-15-009892 · doc4.xml · derivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,000 Underlying: Common Stock · 213,000 shares Expires 2025-02-02 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2015. Read SEC document |
| February 03, 2015 Filed Feb 5, 2015 22:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 64,500 | $0.01 | $645.00 |
DisclosureSEC source: 0001209191-15-009892 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,177 F1 · shares: Performance-based restricted stock award that will vest as to (i) 50% of the shares on the earlier to occur of (a) the attainment of a specified level of net product sales in the United States of lumacaftor in combination with ivacaftor over four calendar quarters and (b) the announcement of the results of a clinical trial establishing proof-of-concept for a next generation CFTR corrector and (ii) 50% of the shares on the earlier to occur of (a) the attainment of a specified level of net product sales outside of the United States of lumacaftor in combination with ivacaftor over four calendar quarters and (b) the announcement of the results from a successful pivotal clinical trial for a non-cystic fibrosis drug candidate sufficient to support the filing of an NDA. Read SEC document |
| December 15, 2014 Filed Dec 16, 2014 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $120.17 | $24,034.00 |
DisclosureSEC source: 0001209191-14-075849 · doc4.xml · nonDerivative · entry 9 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,677 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| December 15, 2014 Filed Dec 16, 2014 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $119.00 | $23,800.00 |
DisclosureSEC source: 0001209191-14-075849 · doc4.xml · nonDerivative · entry 8 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,877 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| December 15, 2014 Filed Dec 16, 2014 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,700 | $118.05 | $318,735.00 |
DisclosureSEC source: 0001209191-14-075849 · doc4.xml · nonDerivative · entry 7 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,077 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F4 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $118.05 (range $117.74 to $118.64). Read SEC document |
| December 15, 2014 Filed Dec 16, 2014 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 8,650 | $117.26 | $1,014,299.00 |
DisclosureSEC source: 0001209191-14-075849 · doc4.xml · nonDerivative · entry 6 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,777 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F4 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $117.26 (range $116.74 to $117.73). Read SEC document |
| December 15, 2014 Filed Dec 16, 2014 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,400 | $116.27 | $395,318.00 |
DisclosureSEC source: 0001209191-14-075849 · doc4.xml · nonDerivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,427 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F4 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $116.27 (range $115.73 to $116.70). Read SEC document |
| December 15, 2014 Filed Dec 16, 2014 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6,406 | $115.05 | $737,010.30 |
DisclosureSEC source: 0001209191-14-075849 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,827 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F4 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $115.05 (range $114.69 to $115.68). Read SEC document |
| December 15, 2014 Filed Dec 16, 2014 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 15,440 | $114.21 | $1,763,402.40 |
DisclosureSEC source: 0001209191-14-075849 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,233 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F4 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $114.21 (range $113.66 to $114.65). Read SEC document |
| December 15, 2014 Filed Dec 16, 2014 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 13,021 | $113.19 | $1,473,846.99 |
DisclosureSEC source: 0001209191-14-075849 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,673 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Open market sales reported on this line occurred at a weighted average price of $113.19 (range $112.66 to $113.65). F4 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| December 12, 2014 Filed Dec 16, 2014 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GiftCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-14-075849 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,694 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · shares: Represents a gift made to a charitable donor-advised fund. Read SEC document |
| December 10, 2014 Filed Dec 12, 2014 21:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 125,000 | $0.01 | $1,250.00 |
DisclosureSEC source: 0001209191-14-074996 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,194 F1 · shares: Performance-based retention award that will vest if performance objectives are achieved prior to November 15, 2019. The award will vest on December 10, 2017 if the Company achieves positive EBITDA for the 12-month period ending September 30, 2017. Between January 1, 2018 and November 15, 2019, if the Company achieves positive EBITDA for a 12-month period ending on a calendar quarter, the award will vest on the day following the applicable earnings release. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $29.98 | $0.00 |
DisclosureSEC source: 0001209191-14-060604 · doc4.xml · derivative · entry 7 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,108 Underlying: Common Stock · 200,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments from 12/14/2011. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 41,704 | $113.90 | $4,750,085.60 |
DisclosureSEC source: 0001209191-14-060604 · doc4.xml · nonDerivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,992 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $113.90 (range $113.61 to $114.41). Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 53,750 | $113.10 | $6,079,125.00 |
DisclosureSEC source: 0001209191-14-060604 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,696 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $113.10 (range $112.61 to $113.60). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.